Availability and applications of ATP-binding cassette (ABC) transporter blockers

Applied Microbiology and Biotechnology

Volumn 76, Issue 2, 2007, Pages 279-286

  Ponte Sucre, Alicia ^a,b  

^a UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

ABC transporter blockers; ABC transporters; Drug resistance; Microorganisms

Indexed keywords

ABC TRANSPORTER BLOCKERS; ABC TRANSPORTERS; CHEMOTHERAPEUTIC FAILURE; DRUG RESISTANCE; PATHOGENESIS;

ADENOSINETRIPHOSPHATE; ANTIGENS; BIOLOGICAL MEMBRANES; HYDROLYSIS; MICROORGANISMS; SIGNAL TRANSDUCTION;

PROTEINS;

5 [3 (4 DIPHENYLACETYL 1 PIPERAZINYL) 2 HYDROXYPROPOXY]QUINOLINE; ABC TRANSPORTER; ABC TRANSPORTER BLOCKER; ALMITRINE; AMIODARONE; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIPARASITIC AGENT; BIRICODAR; BLOCKING AGENT; CHLOROQUINE; CLARITHROMYCIN; CLOMIPRAMINE; CYCLOSPORIN A; DACTINOMYCIN; DOXORUBICIN; ELACRIDAR; EMETINE; ERYTHROMYCIN; FLAVONOID; HYDROXYCHLOROQUINE; IMIPRAMINE; LANIQUIDAR; LIDOCAINE; MEPACRINE; OC 144093; PAROXETINE; QUINIDINE; QUININE; TACROLIMUS; TAMOXIFEN; TARIQUIDAR; TERFENADINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; VINBLASTINE; VX 853; ZOSUQUIDAR;

CANCER; CHEMOTHERAPY; DISEASE TREATMENT; DRUG RESISTANCE; EUKARYOTE; FUNGUS; HYDROLYSIS; NUTRITION; PATHOGENICITY; PROTEIN; SOLUTE TRANSPORT;

ANTIGEN PRESENTATION; CARDIOTOXICITY; CLINICAL TRIAL; DRUG DESIGN; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG TREATMENT FAILURE; EUKARYOTE; FUNGUS SPORE; HUMAN; HYDROLYSIS; INFECTION; LEISHMANIASIS; MEMBRANE TRANSPORT; MOLECULAR MECHANICS; MULTIDRUG RESISTANCE; NONHUMAN; NUTRITION; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN SECRETION; SHORT SURVEY; SIGNAL TRANSDUCTION; SOLUTE; SPOROGENESIS; STRUCTURE ACTIVITY RELATION; UNSPECIFIED SIDE EFFECT;

ADENOSINE TRIPHOSPHATE; ATP-BINDING CASSETTE TRANSPORTERS; BACTERIA; BACTERIAL PROTEINS; BIOLOGICAL TRANSPORT; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE;

BACTERIA (MICROORGANISMS); EUKARYOTA; FUNGI;

EID: 34547137649     PISSN: 01757598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00253-007-1017-6     Document Type: Short Survey

References (64)

1. Allen JD, van Loevezijn A, Lakhai JM, van der Valk M, van Tellingen O, Reid G, Schellens JH, Koomen GJ, Schinkel AH (2002) Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther 1:417-425
2. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM (1999) Biochemical and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361-398
3. Balayssac D, Authier N, Cayre A, Coudore F (2005) Does inhibition of P-glycoprotein lead to drug-drug interactions? Toxicol Lett 156:319-329
4. Berger J, Gartner J (2006) X-linked adrenoleukodystrophy: clinical, biochemical and pathogenetic aspects. Biochim Biophys Acta 1763:1721-1732
5. Bisi A, Gobbi S, Rampa A, Belluti F, Piazzi L, Valenti P, Gyemant N, Molnár J (2006) New potent P-glycoprotein inhibitors carrying a polycyclic scaffold. J Med Chem 49:3049-3051
6. Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P, Loor F (1991) In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 51:4226-33
7. Borst P, Evers R, Kool M, Winholds J (2000) A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92:1295-1302
8. Boumendjel A, Baubichon-Cortay H, Trompier D, Perrotton T, Di Pietro A (2005) Anticancer multidrug resistance mediated by MRP1: recent advances in the discovery of reversal agents. Med Res Rev 25:453-472
9. Choi CH, Sun KH, An CS, Yoo JC, Hahm KS, Lee IH, Sohng JK, Kim YC (2002) Reversal of P-glycoprotein-mediated multidrug resistance by 5,6,7,3′, 4′-pentamethoxyflavone (Sinensetin). Biochem Biophys Res Commun 295:832-840
10. Cole S, Deeley RG (1998) Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. BioEssays 20:931-940
11. Dantzig AH, Alwis DP, Burgess M (2003) Considerations in the design and development of transport inhibitors as adjuncts to drug therapy. Adv Drug Deliv Rev 56:133-150
12. Dassa E, Bouige P (2001) The ABC of ABCs: a phylogenetic and functional classification of ABC systems in living organisms. Res Microbiol 152:211-229
13. Dayan G, Jault JM, Baubichon-Cortay H, Baggetto LG, Renoir JM, Baulieu EE, Gros P, Di Pietro A (1997) Binding of steroid modulators to recombinant cytosolic domain from mouse P-glycoprotein in close proximity to the ATP site. Biochemistry 36:15208-15215
14. Dean M, Rzhetsky A, Allikmets R (2006) The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 11:1156-1166
15. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95:15665-15670
16. Ehrmann M, Ehrle R, Hofmann E, Boos W, Schlosser A (1998) The ABC maltose transporter. Mol Microbiol 29:685-694
17. Etian GD, Regev R, Oren G, Asaraf YG (1996) The role of passive trans bilayer drug movement in multidrug resistance and its modulation. J Biol Chem 271:12897-12902
18. Fojo T, Bates S (2003) Strategies for reversing drug resistance. Oncogene 22:7512-7523
19. Fracasso PM (2001) Overcoming drug resistance in ovarian carcinoma. Curr Oncol Rep 3:19-26
20. Gerlach J, Endicott J, Juranka P, Henderson G, Sarangi F, Deuchars K, Ling V (1986) Homology between P-glycoprotein and a bacterial hemolysin transport protein suggests a model for multidrug resistance. Nature 324:485-489
21. Hayeshi R, Masimirembwa C, Mukanganyama S, Ungell ALB (2006) The potential inhibitory effect of antiparasitic drugs and natural products on p-glycoprotein mediated efflux. Eur J Pharm Sci 29:70-81
22. Hendrickse NH, Franssen EJF, van der Graaf WTA, Vaalburg W, de Vries EGE (1999) Visualization of multidrug resistance in vivo. Eur J Nucl Med 25:283-293
23. Higgins CF (1992) ABC transporters: from microorganisms to man. Annu Rev Cell Biol 8:67-113
24. Higgins CF (2007) Multiple molecular mechanisms for multidrug resistance transporters. Nature 446:749-757
25. Holland IB, Blight MA (1999) ABC-ATPases, adaptable energy generators fueling transmembrane movement of a variety of molecules in organisms from bacteria to humans. J Mol Biol 293:381-399
26. Hyde SC, Emsley P, Harthshorn MJ, Mimmack MM, Gileadi U, Pearce SR, Gallager MP, Gill DR, Hubbard RE, Higgins CF (1990) Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature 346:362-365
27. Jones PM, George AM (2005) Multidrug resistance in parasites: ABC transporters, p-glycoproteins and molecular modeling. Int J Parasitol 35:555-566
28. Kamau SW, Kramer SD, Matja G, Wunderli-Allenspach H (2005) Effect of the modulation of the membrane lipid composition on the localization and function of P-glycoprotein in mdr1-mdck cells. In Vitro Cell Dev Biol Anim 41:207-216
29. Karászi E, Jakab K, Homolya L, Szakács G, Holló Z, Telek B, Kiss A, Rejtô L, Nahajevsky S, Sarkadi B, Kappelmayer J (2001) Calcein assay for multidrug resistance reliably predicts therapy response and survival rate in acute myeloid leukaemia. Br J Haematol 112:308-314
30. Kennedy M, Cortés-Selva F, Pérez Victoria JM, Jiménez IA, González AG, Muñoz OM, Gamarro F, Castanys S, Ravelo AG (2001) Chemosensitization of a multidrug resistant Leishmania tropica line by new sesquiterpenes from Maytenus magellanica and Maytenus chubutensis. J Med Chem 44:4668-4676
31. Kitagawa S (2006) Inhibitory effects of polyphenols on P-glycoprotein-mediated transport. Biol Pharm Bull 29:1-6
32. Krishna R, Mayer LD (2000) Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 11:265-283
33. Klokouzas A, Shahi S, Hladky SB, Barrand MA, van Veen HW (2003) ABC transporters and drug resistance in parasitic protozoa. Int J Antimicrob Agents 22:301-317
34. Lage H (2003) ABC-transporters: implications on drug resistance from microorganisms to human cancers. Int J Antimicrob Agents 22:188-199
35. Leonard GD, Fojo T, Bates SE (2003) The role of ABC transporters in clinical practice. Oncologist 8:411-424
36. Lomovskaya O, Watkins WJ (2001) Efflux pumps: their role in antibacterial drug discovery. Curr Med Chem 8:1699-1771
37. Lomovskaya O, Warren mS, Lee A, Galazzo J, Fronko R, Lee M, Blais J, Cho D, Chanberland S, Renau T (2001) Identification and characterization of inhibitors of multidrug resistance efflux pumps in P. aeruginosa: novel agents for combination. Antimicrob Agents Chemother 45:105-116
38. Machuca C, Rodríguez A, Herrera M, Silva S, Ponte-Sucre A (2006) Metabolic adaptations induced by resistance to glibenclamide in Leishmania amazonensis. Exp Parasitol 114:1-9
39. Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC, Ruevekamp-Helmers MC, Floot BG, Schellens JH (1999) Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 59:4559-4563
40. Mallea M, Mahamoud A, Chevalier J, Albert Franco S, Brounant P, Barbe J, Pages JM (2003) Alkylaminoquinolones inhibit the antibiotic efflux pump in multidrug-resistant clinical isolates. Biochem J 376:801-805
41. McKeegan KS, Borges-Walmsley MI, Walmsley AR (2004) Structural understanding of efflux-mediated drug resistance: potential routes to efflux inhibition. Curr Opin Pharmacol 4:479-486
42. Mullin S, Mani N, Grossman TH (2004) Inhibition of antibiotic efflux in bacteria by the novel multidrug resistance inhibitors biricodar (VX-710) and Timcodar (VX-853). Antimicrob Agents Chemother 48:4171-4176
43. Nelson ML, Levy SB (1999) Reversal of tetracycline resistance mediated by different bacterial tetracycline determinants by an inhibitor of the Tet(B) antiport protein. Antimicrob Agents Chemother 43:1719-1724
44. Paulsen IT (2003) Multidrug efflux pumps and resistance: regulation and evolution. Curr Opin Microbiol 6:446-451
45. Pedersen PL (2005) Transport ATPases: structure, motors, mechanism and medicine: a brief overview. J Bioenerg Biomembr 37:349-357
46. Ponte-Sucre A, Campos Y, Vasquez J, Moll H, Mendoza-León A (1997) Sensitivity of Leishmania spp. to glibenclamide and 4-aminopyridine: a tool for the study of drug resistance development. Mem Inst Oswaldo Cruz 92:601-606
47. Pradines B, Albert-Franco S, Houdoin C, Mosnier J, Santelli-Rouvier C, Papa V, Rogier C, Fusai T, Barbe J, Parzy D (2002) In vitro reversal of chloroquine resistance in Plasmodium falciparum with dihydroethanoanthracene derivatives. Am J Trop Med Hyg 66:661-666
48. Saurin W, Hofnung M, Dassa E (1999) Getting in or out: early segregation between importers and exporters in the evolution of ATP-binding cassette (ABC) transporters. J Mol Evol 48:22-41
49. Seelig A (1998) A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem 251:252-261
50. +(ATP) channels, shows antileishmanial activity in experimental murine cutaneous leishmaniasis. Antimicrob Agents Chemother 50:4214-4216
51. JA Sheps S Ralph Z-Y Zhao DL Baillie V Ling 2004 The ABC transporter gene family of Caenorhabditis elegans has implications for the evolutionary dynamics of multidrug resistance in eukaryotes Genome Biol 5 R15 Sheps JA, Ralph S, Zhao Z-Y, Baillie DL, Ling V (2004) The ABC transporter gene family of Caenorhabditis elegans has implications for the evolutionary dynamics of multidrug resistance in eukaryotes. Genome Biol 5:R15 (URL: http:// genomebiology.com/2004/5/3/R15 )
52. Sheps JA, Ling V (2006) Preface: the concept and consequences of multidrug resistance. Pflugers Arch Eur J Physiol 453:545-553
53. Shilling RA, Venter H, Velamakanni S, Bapna A, Woebking B, Shahi S, van Veen HW (2006) New light on multidrug binding by and ATP-binding-cassette transporter. Trends Pharmacol Sci 27:195-203
54. Silva N, Camacho N, Figarella K, Ponte-Sucre A (2004) Cell differentiation and infectivity of Leishmania mexicana are inhibited in an ABC-transporter blocker resistant strain. Parasitology 128:629-634
55. Stouch TR, Gudmundsson O (2002) Progress in understanding the structure-activity relationships of P-glycoprotein. Adv Drug Deliv Rev 54:315-328
56. Sun J, He ZG, Cheng G, Wang SJ, Hao XH, Zou MJ (2004) Multidrug resistance P-glycoprotein: crucial significance in drug disposition and interaction. Med Sci Monit 10:RA5-RA14
57. Thomas PM, Cote GJ, Wohllk N, Mathew PM, Gagel RF (1996) The molecular basis for familial persistent hyperinsulinemic hypoglycemia of infancy. Proc Assoc Am Physicians 108:14-19
58. Uzcátegui NL, Figarella K, Camacho N, Ponte-Sucre A (2005) Substrate preferences and glucose uptake in glibenclamide-resistant Leishmania parasites. Comp Biochem Physiol 140:395-402
59. van der Heide T, Poolman B (2002) ABC transporters: one, two or four extracytoplasmic substrate binding sites? EMBO Rep 3:938-943
60. van Herwaarden AE, Schinkel AH (2006) The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins. Trends Pharmacol Sci 27:10-16
61. van Veen HW, Konings WN (1997) Multidrug transporters from bacteria to man: similarities in structure and function. Semin Cancer Biol 8:183-191
62. van Veen HW (2001) Towards the molecular mechanism of prokaryotic and eukaryotic multidrug transporters. Semin Cell Dev Biol 12:239-245
63. Varma MV, Ashokraj Y, Dey CS, Panchagnula R (2003) P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol Res 48:347-359
64. Wiese M, Pajeva IK (2001) Structure-activity of multidrug resistance reversers. Curr Med Chem 8:685-713